We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
The current OPHLY market cap is 7.16B. The company's latest EPS is JPY 76.9478 and P/E is 0.21.
| Year End March 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Revenue | 288.63B | 293.08B | 317.35B | 362.34B | 447.92B |
| Operating Income | 64.55B | 77.35B | 98.34B | 103.25B | 142.06B |
| Net Income | 51.54B | 59.7B | 75.43B | 80.52B | 112.72B |
| Year End March 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Assets | 655.06B | 673.44B | 746.84B | 739.2B | 882.44B |
| Total Liabilities | 92.32B | 105.42B | 105.69B | 77.53B | 134.63B |
| Total Equity | 562.74B | 568.02B | 641.16B | 661.67B | 747.81B |
| Year End March 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Operating | 66.77B | 74.16B | 73.98B | 61.82B | 159.61B |
| Investing | -49.76B | -10.23B | -57.59B | 6.04B | -100.26B |
| Financing | -22.28B | -54.72B | -24.75B | -60.23B | -32.49B |
| Market Cap | 7.16B |
| Price to Earnings Ratio | 0.21 |
| Price to Sales Ratio | 0.05 |
| Price to Cash Ratio | 0.24 |
| Price to Book Ratio | 0.03 |
| Dividend Yield | - |
| Shares Outstanding | 1.46B |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0.06 (1.22%) |
| Company Name | Ono Pharmaceutical Company Ltd (PK) |
| Address |
1-8-2 kyutaromachi chuo, tokyo 541-8564 |
| Website | https://www.ono.co.jp |
| Industry | pharmaceutical diversified (H2) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
